John Beadle
4-10 The Quadrant, Barton Lane
Abingdon, ENG, United Kingdom
Abingdon, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
Journal: Journal for immunotherapy of cancer
Published: July 31, 2018
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
Journal: Journal for immunotherapy of cancer
Published: April 20, 2017
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.
Journal: Molecular therapy oncolytics
Published: December 08, 2016
Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.
Journal: Molecular therapy oncolytics
Published: July 19, 2016
Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial).
Journal: Journal of cachexia, sarcopenia and muscle
Published: January 27, 2016
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.
Journal: European heart journal
Published: August 31, 2013
The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats.
Journal: Journal of cachexia, sarcopenia and muscle
Published: June 27, 2013
Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.
Journal: International journal of cardiology
Published: October 16, 2012
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design.
Journal: Journal of cachexia, sarcopenia and muscle
Published: October 03, 2011
Showing 1-9 of 9
Last Updated: 09/26/2026